Hepatic Injury, Concanavalin A (Con-A)-Induced

  1. image
CONTACT CUSTOMER SERVICE
  ADD TO FAVORITES
  ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
RELATED SERVICES
RELATED PRODUCTS
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
Concanavalin A (Con A)-induced liver injury is a mouse model of immune-mediated liver injury that resembles viral and autoimmune hepatitis in humans. The aim of this study model is to investigate the effects of test substances on liver injury induced by Con A.
ORGANISM
Mouse
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Group of 6 male BALB/c mice weighing 24 ± 2 g is fasted overnight prior to use. Test article is administered by oral gavage at 0.5 hour before Concanavalin A (Con A, 15 mg/kg, i.v.) as well as 4 and 8 hours after Con A. The animals are sacrificed 24 hours after administration of Con A and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are measured by automated biochemical analyzer TBA-120FR. Additional analyses that can be requested include ALP, T-BIL and ALB levels, liver weight, biomarker analysis (protein and/or mRNA) and histopathology etc. Doses may be administered PO, IV, IP and SC. Suggested Testing: n=6/group (study design dependent).
CRITERIA FOR SIGNIFICANCE
p<0.05 compared to vehicle control is considered significant activity
TURNAROUND TIME
STANDARD
20 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Inflammation/Allergy
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.

 

© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences